Trials / Completed
CompletedNCT06160895
A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TQ-A3334 Tablet After Multiple Doses in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects. The primary objective is to evaluate the safety and tolerability of multiple dosing of TQ-A3334 tablets in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-A3334 tablets | TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist. |
| DRUG | TQ-A3334 placebo tablets | TQ-A3334 placebo tablet is a placebo that has no effect on TLR7. |
Timeline
- Start date
- 2023-12-26
- Primary completion
- 2024-06-24
- Completion
- 2024-08-19
- First posted
- 2023-12-07
- Last updated
- 2024-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06160895. Inclusion in this directory is not an endorsement.